세계의 전임상 이미징 시장 규모 : 모달리티별, 용도별, 최종 사용자별, 지리적 범위 및 예측

Global Preclinical Imaging Market Size By Modality, By Application, By End-User By Geographic Scope And Forecast

US $ 3,950 ￦ 5,493,000

PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 보고서의 다운로드와 인쇄가 가능합니다.

US $ 4,850 ￦ 6,745,000

PDF & Excel (5 User License)

PDF 및 Excel 보고서를 동일 기업의 5명까지 이용할 수 있는 라이선스입니다. 보고서의 다운로드와 인쇄가 가능합니다.

US $ 7,550 ￦ 10,500,000

PDF & Excel (Enterprise User License)

PDF 및 Excel 보고서를 동일기업내 모든 분들이 이용할 수 있는 라이선스입니다. 보고서의 다운로드와 인쇄가 가능합니다.

한글목차

전임상 이미징 시장 규모와 예측

전임상 이미징 시장 규모는 2024년에 9억 5,755만 달러로 평가되었고 2026-2032년에 걸쳐 CAGR 5.12%를 나타내 2032년에는 14억 2,772만 달러에 달할 것으로 예측되고 있습니다.

• 전임상 이미징은 인간 임상 검사 전에 동물 모델에서 생물학적 과정을 조사하는 데 사용되는 첨단 이미징 기술의 모음입니다. 질병개발을 추적하고 생체내에서의 치료반응을 평가할 수 있습니다.
• 전임상 이미징에는 이미지 처리와 해석을 개선하기 위한 인공지능과 머신러닝이 통합되어 대폭적인 브레이크스루의 준비가 갖추어져 있습니다.
• 맞춤형 의료가 중시되게 되면, 의약품에 대한 개별 반응을 예측할 수 있는 맞춤형 이미징 기술의 개발이 촉진되어 최종적으로는 트랜스레이셔널 연구의 성과를 높여 인간 임상 검사에의 길을 가속하게 될 것으로 예측됩니다.

세계의 전임상 이미징 시장 역학

세계의 전임상 이미징 시장을 형성하는 주요 시장 역학은 다음과 같습니다.

주요 시장 성장 촉진요인

• 의약품 R&D 투자 증가 : NIH에 따르면 제약 회사는 2023년 R&D에 950억 달러를 투자해 2020년부터 32% 증가했습니다. 또한 FDA는 2021-2023년 사이에 전임상 이미징을 필요로 하는 임상시험약 신청이 45% 증가했다고 밝혔습니다. 이 급증은 PhRMA의 조사 결과에서 알 수 있듯이 치료 효과와 안전성에 대한 보다 정확하고 상세한 데이터에 대한 수요에 의해 초래되고 있으며, 현재 의약품 개발 프로그램의 78%가 선진적 전임상 이미징을 사용하고 있으며 2020년의 52%에서 증가하고 있습니다. 이 성장은 의약품 개발의 신속화, 검사 설계의 개선, 성공률의 향상에 있어서 이미징이 중요한 역할을 담당하고 있음을 나타냅니다.
• 만성 질환의 만연 : 만성 질환 증가는 보다 우수한 전임상 연구 도구의 필요성을 증가시키고 있습니다. WHO에 따르면 암 환자는 2040년까지 60% 증가할 것으로 예상되고 CDC에 따르면 미국인 10명 중 6명은 이미 적어도 하나의 만성 질환을 앓고 있습니다. 이러한 증가의 배경으로는 조기 발견, 정확한 질병 모델링 및 치료법 개발의 개선이 있습니다. 미국 국립암 실험실은 전임상 이미징에 대한 자금 제공을 89% 증가시켰고, 2023년에는 총액 28억 달러에 달했다고 발표했으며, 이러한 건강 우려의 증대에 대처하는데 있어서 이미징이 매우 중요하다는 것을 강조하고 있습니다.
• 이미징 모달리티의 기술적 진보 : 이미징 모달리티의 기술적 진보는 전임상 이미징의 능력을 크게 향상시켰으며, 그 결과 연구에서의 활용도가 증가하고 있습니다. Medical Imaging and Technology Alliance에 의하면, 2021-2023년 사이에 이미징 시스템의 정밀도는 156% 향상, 멀티 모달 어프로치는 234% 증가해, 보다 종합적인 데이터 수집이 가능하게 되었습니다.

주요 이슈

• 이미징 시스템의 고비용 : MRI, PET, CT 등의 고급 전임상 이미징 기술은 구매 및 유지에 비용이 듭니다. 넓은 이용이 제한되어 있습니다.고액의 비용은 연구비 전체를 증가시켜 제약회사의 연구개발 예산에 타격을 줍니다.
• 데이터 관리 및 스토리지 문제 : 전임상 이미징은 대량의 데이터를 생성하므로 적절하게 저장, 처리, 분석해야 합니다. 그 결과 데이터 처리와 분석이 비효율적으로 되어 있습니다.
• 긴 개발과 상품화 사이클 : 새로운 전임상 이미징 기술을 개발하고 시장에 투입하려면 대규모 연구개발, 약사 승인 프로세스가 필요합니다. 시장의 성장이 제한될 가능성이 있습니다.또, 이러한 긴 그린 사이클은 특히 중소기업에 있어서는 투자 회수의 실현에 수년도 걸릴 가능성이 있어, 시장 역학에 영향을 주기 때문에 투자 의욕을 감퇴시키고 있습니다.

주요 동향

• 멀티 모달 이미징 기술의 사용 증가 : MRI, PET, CT 등 여러 이미지 모드를 결합한 멀티 모달 이미징 기술의 사용이 증가하고 있으며 전임상 연구에서 생물학적 프로세스를 완벽하게 조사 할 수 있습니다.의 동향은 질병의 발생과 치료 효과에 대해 보다 완전하고 종합적인 이해를 제공함으로써 데이터의 질을 향상시키고 있습니다.
• 비 침습적 이미징 방법으로의 이동 : 비 침습적 이미징 기술은 동물 모델에 해를 끼치지 않고 질병의 진행을 추적 할 수 있기 때문에 인기를 끌고 있습니다. 연구자들은 귀중한 종단적 데이터를 얻을 수 있습니다.
• 분자 이미징의 성장 : 세포와 분자의 과정을 볼 수있는 분자 이미징은 전임상 연구에서 중요성을 늘리고 있습니다. 그 결과, 조기 발견이나 보다 정확한 치료 목표가 가능해집니다.맞춤형 의료가 가속하는 가운데, 분자 이미징은 표적 의약품의 창제에 중요한 역할을 하고, 전임상 연구에서의 이용이 증가해, 시장 성장을 뒷받침하고 있습니다.

목차

제1장 세계의 전임상 이미징 시장 도입

• 시장 개요
• 조사 범위
• 전제조건

제2장 주요 요약

제3장 VERIFIED MARKET RESEARCH의 조사 방법

• 데이터 마이닝
• 밸리데이션
• 1차 자료
• 데이터 소스 일람

제4장 세계의 전임상 이미징 시장 전망

• 개요
• 시장 역학
  • 성장 촉진요인
  • 성장 억제요인
  • 기회

제5장 세계의 전임상 이미징 시장 : 모달리티별

• 개요
• 자기 공명 영상
• 컴퓨터 단층 촬영
• 포지트론 CT
• 단일 광자 방출 컴퓨터 단층 촬영법
• 광학 이미징
• 초음파 이미징

제6장 세계의 전임상 이미징 시장 : 용도별

• 개요
• 종양학
• 신경학
• 심장학
• 염증
• 감염성 질환
• 대사성 질환

제7장 세계의 전임상 이미징 시장 : 최종 사용자별

• 개요
• 제약 및 바이오테크놀러지 기업
• 계약 연구 기관
• 연구기관 및 학술센터
• 병원 및 클리닉

제8장 세계의 전임상 이미징 시장 : 지역별

• 개요
• 북미
  • 미국
  • 캐나다
  • 멕시코
• 유럽
  • 독일
  • 영국
  • 프랑스
  • 기타 유럽
• 아시아태평양
  • 중국
  • 일본
  • 인도
  • 기타 아시아태평양
• 기타
  • 라틴아메리카
  • 중동 및 아프리카

제9장 세계의 전임상 이미징 시장 경쟁 구도

• 개요
• 각사 시장 랭킹
• 주요 개발 전략

제10장 기업 프로파일

• Bruker Corporation
• Siemens AG
• General Electric
• TriFoil Imaging
• PerkinElmer, Inc.
• VisualSonics Inc.(Fujifilm)
• Mediso Ltd.
• Agilent Technologies
• MILabs BV
• MR Solutions

제11장 주요 개발

• 제품 출시/개발
• 합병과 인수
• 사업 확대
• 파트너십과 제휴

제12장 부록

• 관련 조사

KTH

영문 목차

영문목차

Preclinical Imaging Market Size And Forecast

Preclinical Imaging Market size was valued at USD 957.55 Million in 2024 and is projected to reach USD 1427.72 Million by 2032, growing at a CAGR of 5.12% from 2026 to 2032.

• Preclinical imaging is a collection of advanced imaging techniques used to examine biological processes in animal models before human clinical trials. These techniques, which include MRI, PET, CT, and bioluminescence imaging, enable researchers to study the effects of novel medications, follow disease development, and assess therapy responses in vivo. Preclinical imaging is important in drug discovery and development because it allows scientists to collect key data on the efficacy and safety of new treatments, as well as examine pharmacokinetics and improve study designs.
• Preclinical imaging is poised for substantial breakthroughs with the incorporation of artificial intelligence and machine learning to improve picture processing and interpretation. As imaging technologies advance, we should expect increased sensitivity and resolution, allowing for more exact assessments of biological processes at the molecular level.
• The increased emphasis on customized medicine is likely to stimulate the development of tailored imaging techniques capable of predicting individual responses to medicines, ultimately enhancing translational research outcomes and expediting the journey to human clinical trials.

Global Preclinical Imaging Market Dynamics

The key market dynamics that are shaping the global preclinical imaging market include:

Key Market Drivers:

• Rising Investment in Pharmaceutical R&D: Rising investment in pharmaceutical R&D is fueling robust growth in the preclinical imaging market, with pharmaceutical companies investing USD 95 Billion in R&D in 2023, up 32% from 2020, according to the NIH. The FDA also forecasts a 45% increase in investigational new medication applications that need preclinical imaging between 2021 and 2023. This spike is being driven by the demand for more precise, in-depth data on therapeutic efficacy and safety, as indicated by PhRMA's findings that 78% of drug development programs currently use advanced preclinical imaging, up from 52% in 2020. This growth underlines imaging's critical role in expediting drug development, refining study designs, and increasing success rates.
• Growing Prevalence of Chronic Diseases: The increasing frequency of chronic diseases is driving the need for better preclinical research tools. Cancer cases are expected to climb by 60% by 2040, according to the WHO, and 6 out of 10 Americans already have at least one chronic ailment, according to the CDC, resulting in a 67% increase in preclinical research since 2021. This increase is motivated by the need for early identification, precise disease modeling, and improved treatment development. The National Cancer Institute's 89% increase in funding for preclinical imaging, totaling $2.8 billion in 2023, emphasizes the critical significance of imaging in addressing these growing health concerns.
• Technological Advancements in Imaging Modalities: Technological advancements in imaging modalities are greatly improving the capabilities of preclinical imaging, resulting in its increased use in research. The Medical Imaging and Technology Alliance estimated that imaging system precision improved by 156% between 2021 and 2023, while multimodal approaches increased by 234%, allowing for more comprehensive data collection, according to the European Society of Molecular Imaging. According to the Journal of Nuclear Medicine, AI-enhanced imaging will decrease research durations by 42% and improve accuracy by 68% in 2023.

Key Challenges:

• High Cost of Imaging Systems: Advanced preclinical imaging technologies, including as MRI, PET, and CT, are expensive to purchase and maintain. These systems can cost millions of dollars, making them unavailable to smaller research institutes and limiting their broad use. The high costs increase overall research expenses, hurting pharmaceutical companies' R&D budgets. This challenge stifles market expansion since affordability becomes a hurdle, particularly in emerging markets.
• Data Management and Storage Issues: Preclinical imaging produces a large amount of data, which must be appropriately saved, handled, and analyzed. Many institutions lack the necessary infrastructure and skills to manage massive datasets, resulting in inefficiencies in data processing and analysis. Poor data management can jeopardize research quality, delay projects, and raise operational expenses, posing a substantial impediment to market expansion, especially as imaging technologies advance.
• Long Development and Commercialization Cycles: Creating new preclinical imaging technologies and bringing them to market requires extensive research, development, and regulatory approval processes. The slow rate of invention and commercialization might cause delays in the adoption of new imaging technologies, limiting market growth. This protracted cycle also discourages investment, particularly from smaller enterprises, because the return on investment might take years to realize, influencing market dynamics.

Key Trends:

• Increasing Use of Multimodal Imaging Techniques: The increasing use of multimodal imaging techniques, which combine several imaging modalities such as MRI, PET, and CT, allows for complete investigation of biological processes in preclinical studies. This trend improves data quality by providing a more complete and comprehensive understanding of illness development and treatment efficacy. The capacity to collect more robust and diversified data in a single experiment is boosting demand for these integrated technologies, which increase research efficiency.
• Shift to Non-invasive Imaging Methods: Non-invasive imaging techniques are gaining popularity due to their ability to track disease progression without causing harm to the animal model. Methods such as optical imaging and MRI allow for repeated observations throughout time, giving researchers valuable longitudinal data. This shift toward non-invasive techniques is increasing demand for sophisticated preclinical imaging technologies, which lessen ethical issues while also improving experimental data quality.
• Growth in Molecular Imaging: Molecular imaging, which allows for the viewing of cellular and molecular processes, is becoming more important in preclinical research. It enables researchers to investigate disease pathways at the molecular level, resulting in earlier identification and more precise treatment targeting. As personalized medicine gains pace, molecular imaging plays an important role in creating targeted medicines, increasing usage in preclinical investigations, and propelling market growth.

Global Preclinical Imaging Market Regional Analysis

Here is a more detailed regional analysis of the global preclinical imaging market:

North America:

• North America's dominance in the preclinical imaging market is primarily due to its strong pharmaceutical and biotechnology sectors. The United States accounts for about half of the global market, owing to considerable investments in research and infrastructure. As of 2023, the National Institutes of Health (NIH) reported a 156% growth in preclinical imaging spending, totaling USD 12.7 Billion. This expansion is being driven by an increasing need for improved imaging technologies in drug discovery and development, notably with the rise of customized medicine.
• Pharmaceutical companies have increasingly utilized preclinical imaging, with the United States Food and Drug Administration (FDA) reporting an 89% increase in companies adopting these technologies between 2021 and 2023. Canada's biotechnology sector also contributes, with preclinical imaging expenditures increasing by 178%, reinforcing North America's leading spot.
• Investment in research and development (R&D) is critical to boosting North America's preclinical imaging market. The National Science Foundation reports that between 2020 and 2023, private-sector R&D spending on imaging increased by 234%, reaching USD 18.5 Billion. This is supplemented by a predicted 67% increase in federal funding for preclinical research by 2026. Technological developments have also been important drivers, with institutions purchasing 45% more preclinical imaging equipment in 2023 compared to 2021. Such infrastructure expansion has resulted in speedier drug development schedules, with the FDA reporting a 145% increase in medication applications that include preclinical imaging data. This incorporation of imaging technology into drug discovery speeds up the research process and increases success rates, consolidating North America's market leadership.

Asia Pacific:

• The Asia Pacific region is experiencing tremendous expansion in the preclinical imaging market, making it the fastest-growing market globally. Between 2021 and 2023, the market grew by 189% to USD 5.8 Billion, owing to increased investments in healthcare infrastructure and technology improvements. China, Japan, and India have greatly increased funding for preclinical research. China's investment alone increased by 234% to ¥45.6 billion (USD 7.1 Billion) during this period. Government initiatives, such as public-private partnerships and collaborations between academic institutions and pharmaceutical businesses, have also increased, adding to market growth. The expansion of preclinical imaging facilities in South Korea and Australia demonstrates the region's growing commitment to complex research capabilities, establishing Asia Pacific as a focus for medical imaging innovation.
• Population growth and increased healthcare spending are also propelling Asia Pacific's preclinical imaging market. As the middle class grows and discretionary income improves, healthcare spending in the region climbed by 89% between 2021 and 2023. The World Bank anticipates that by 2025, 45% of the region's population will have access to advanced healthcare services, greatly increasing demand for breakthrough medical technology such as preclinical imaging. Rising research efforts and government-sponsored collaborations are creating a favorable atmosphere for preclinical imaging improvements, hastening expansion in the region.

Global Preclinical Imaging Market: Segmentation Analysis

The Global Preclinical Imaging Market is Segmented on the basis of Modality, Application, End-User, And Geography.

Preclinical Imaging Market, By Modality

• Magnetic Resonance Imaging
• Computed Tomography
• Optical Imaging
• Ultrasound Imaging

Based on Modality, the market is bifurcated into Magnetic Resonance Imaging, Computed Tomography, Optical Imaging, and Ultrasound Imaging. Magnetic Resonance Imaging (MRI) leads the preclinical imaging market due to its high resolution and non-invasive nature, making it perfect for precise anatomical and functional analyses. The broad use of MRI in neurological and cancer research has cemented its position as the leading technology. Optical Imaging is the fastest expanding segment, thanks to its capacity to deliver real-time molecular imaging with little invasiveness. Its rapid expansion is being driven by increased demand in oncology and cardiovascular research, where early-stage drug discovery necessitates sensitive, real-time imaging of biologic processes.

Preclinical Imaging Market, By Application

• Research and Development
• Drug Discovery

Based on Application, the market is segmented into Research and Development and Drug Discovery. Drug discovery is the dominant segment in the preclinical imaging market due to its critical role in determining medication efficacy and safety prior to clinical testing. Drug discovery is the most important application because to rising demand for precision medicine and increased pharmaceutical R&D investments. The fastest-growing category is research and development (R&D), which is driven by increased investment in breakthrough technologies and the need for enhanced imaging techniques to hasten the discovery of new medicines, notably in oncology and neurological disorders.

Preclinical Imaging Market, By End-User

• Pharmaceutical and Biotechnology Companies
• Research Institutes

Based on End-User, the market is segmented into Pharmaceutical and Biotechnology Companies and Research Institutes. Pharmaceuticals and Biotechnology Companies dominate the preclinical imaging market because they make substantial use of imaging technologies in drug development and testing. Their enormous investments in R&D, along with the quest for speedier drug discovery methods, position them as the market leader. Research institutes are the fastest-growing segment, owing to increased government financing and academic-industry cooperation. These institutes are quickly using advanced imaging technologies to support cutting-edge research, including disease models and therapeutic development.

Preclinical Imaging Market, By Geography

• North America
• Europe
• Asia Pacific
• Rest of the World
• On the basis of Geography, the Global Preclinical Imaging Market is classified into North America, Europe, Asia Pacific, and the Rest of the World. North America dominates the preclinical imaging market thanks to its strong pharmaceutical and biotechnology industries, superior infrastructure, and large R&D investments. The Asia Pacific region is witnessing the quickest growth, owing to rising healthcare spending, increased research activity, and increased awareness of preclinical imaging techniques.

Key Players

The "Global Preclinical Imaging Market" study report will provide valuable insight with an emphasis on the global market. The major players in the market are Bruker Corporation, Siemens A.G., General Electric, TriFoil Imaging, PerkinElmer, Inc., VisualSonics, Inc., Mediso Ltd., Agilent Technologies, MILabs B.V., MR Solutions, and Molecube. The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players globally.

Our market analysis also entails a section solely dedicated to such major players wherein our analysts provide an insight into the financial statements of all the major players, along with product benchmarking and SWOT analysis. The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players globally.

• Preclinical Imaging Market Recent Developments
• In April 2024, Spectral Instruments Imaging announced the release of Aura 4.5, the most recent version of its in vivo imaging software.
• In April 2023, Southern Scientific announced that it will become the new UK distributor for Spectral Instruments Imaging, a leading provider of preclinical in vivo imaging equipment.

TABLE OF CONTENTS

1 INTRODUCTION OF GLOBAL PRECLINICAL IMAGING MARKET

• 1.1 Overview of the Market
• 1.2 Scope of Report
• 1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

• 3.1 Data Mining
• 3.2 Validation
• 3.3 Primary Interviews
• 3.4 List of Data Sources

4 GLOBAL PRECLINICAL IMAGING MARKET OUTLOOK

• 4.1 Overview
• 4.2 Market Dynamics
  • 4.2.1 Drivers
  • 4.2.2 Restraints
  • 4.2.3 Opportunities

5 GLOBAL PRECLINICAL IMAGING MARKET, BY MODALITY

• 5.1 Overview
• 5.2 Magnetic Resonance Imaging
• 5.3 Computed Tomography
• 5.4 Positron Emission Tomography
• 5.5 Single Photon Emission Computed Tomography
• 5.6 Optical Imaging
• 5.7 Ultrasound Imaging

6 GLOBAL PRECLINICAL IMAGING MARKET, BY APPLICATION

• 6.1 Overview
• 6.2 Oncology
• 6.3 Neurology
• 6.4 Cardiology
• 6.5 Inflammation
• 6.6 Infectious Diseases
• 6.7 Metabolic Diseases

7 GLOBAL PRECLINICAL IMAGING MARKET, BY END-USERS

• 7.1 Overview
• 7.2 Pharmaceutical & Biotechnology Companies
• 7.3 Contract Research Organizations
• 7.4 Research Institutions & Academic Centers
• 7.5 Hospitals & Clinics

8 GLOBAL PRECLINICAL IMAGING MARKET, BY GEOGRAPHY

• 8.1 Overview
• 8.2 North America
  • 8.2.1 U.S.
  • 8.2.2 Canada
  • 8.2.3 Mexico
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 U.K.
  • 8.3.3 France
  • 8.3.4 Rest of Europe
• 8.4 Asia Pacific
  • 8.4.1 China
  • 8.4.2 Japan
  • 8.4.3 India
  • 8.4.4 Rest of Asia Pacific
• 8.5 Rest of the World
  • 8.5.1 Latin America
  • 8.5.2 Middle East & Africa

9 GLOBAL PRECLINICAL IMAGING MARKET COMPETITIVE LANDSCAPE

• 9.1 Overview
• 9.2 Company Market ranking
• 9.3 Key Development Strategies

10 COMPANY PROFILES

• 10.1 Bruker Corporation
  • 10.1.1 Overview
  • 10.1.2 Financial Performance
  • 10.1.3 Product Outlook
  • 10.1.4 Key Developments
• 10.2 Siemens A.G.
  • 10.2.1 Overview
  • 10.2.2 Financial Performance
  • 10.2.3 Product Outlook
  • 10.2.4 Key Developments
• 10.3 General Electric
  • 10.3.1 Overview
  • 10.3.2 Financial Performance
  • 10.3.3 Product Outlook
  • 10.3.4 Key Developments
• 10.4 TriFoil Imaging
  • 10.4.1 Overview
  • 10.4.2 Financial Performance
  • 10.4.3 Product Outlook
  • 10.4.4 Key Developments
• 10.5 PerkinElmer, Inc.
  • 10.5.1 Overview
  • 10.5.2 Financial Performance
  • 10.5.3 Product Outlook
  • 10.5.4 Key Developments
• 10.6 VisualSonics Inc. (Fujifilm)
  • 10.6.1 Overview
  • 10.6.2 Financial Performance
  • 10.6.3 Product Outlook
  • 10.6.4 Key Developments
• 10.7 Mediso Ltd.
  • 10.7.1 Overview
  • 10.7.2 Financial Performance
  • 10.7.3 Product Outlook
  • 10.7.4 Key Developments
• 10.8 Agilent Technologies
  • 10.8.1 Overview
  • 10.8.2 Financial Performance
  • 10.8.3 Product Outlook
  • 10.8.4 Key Developments
• 10.9 MILabs B.V.
  • 10.9.1 Overview
  • 10.9.2 Financial Performance
  • 10.9.3 Product Outlook
  • 10.9.4 Key Developments
• 10.10 MR Solutions
  • 10.10.1 Overview
  • 10.10.2 Financial Performance
  • 10.10.3 Product Outlook
  • 10.10.4 Key Developments

11 KEY DEVELOPMENTS

• 11.1 Product Launches/Developments
• 11.2 Mergers and Acquisitions
• 11.3 Business Expansions
• 11.4 Partnerships and Collaborations

12 APPENDIX

• 12.1 Related Research

관련자료